Work

An LPS-functionalized nanoplatform facilitating immune re-education and NET suppression for eradication of postoperative residual tumors in ovarian cancer

Year: 2026
Type: article
Abstract: The prognosis of patients with ovarian cancer (OC) after standardized cytoreductive surgery plus platinum-based chemotherapy is still poor owing to minimal residual tumors and the immunosuppressive “cold tumor” microenvironment. Furthermore, inefficient drug delivery and neutrophil extracellular trap (NET)-driven metastasis lead to worse survival. Therefore, the development of a multifunctional drug that can overcome these obstacles in postoperative OC therapy is urgently needed. A lipopolysaccharide (LPS)-functionalized nanocarrier (L-Lip@CC) was engineered to co-deliver cisplatin (CDDP) and specific peptidylarginine deiminases 4 (PAD4) inhibitor Cl-amidine. Its neutrophil hitchhiking delivery, re-educating immune cells, and inhibiting NET formation were evaluated in vitro and in toll-like receptor 4 (TLR4) knockout mice. The efficacy of NET blockade in inhibiting OC metastasis was verified in PAD4 knockout mice. Therapeutic efficacy and safety were validated in OC cell cultures, as well as in orthotopic and metastatic OC mouse models. L-Lip@CC can in situ hitchhike circulating neutrophils via TLR4, thus being precisely delivered to postoperative residual tumors and exerting strong cytotoxicity through DDP. The LPS decorated on the surface of L-Lip@CC reduces the toxicity of free LPS while maintaining superior immunomodulatory capacity. Therefore, L-Lip@CC effectively re-educates antitumor immunity by increasing the infiltration of CD8 + T cells and NK cells, promoting M1-like polarization of tumor-associated macrophages (TAMs), while also effectively inhibiting NETs formation via Cl-amidine, thereby preventing the establishment of a metastatic niche. Collectively, this multifunctional nanoplatform achieves tumor-targeted delivery, thereafter offers a highly promising therapeutic strategy for OC after cytoreductive surgery.
Language: English
Subfield: Biomaterials
Open Access status: gold
Estimated APC paid: $3,790
OpenAlex ID: W7234452659
FWCI:
Cites:
Cited by:
Related to: 10